atrial fibrillation Archives
Feb. 22, 2018—Since launching its program offering patients with non-valvular atrial fibrillation (AF) an alternative treatment to reduce their risk of stroke and avoiding long-term use of blood thinners, the Vanderbilt Heart and Vascular Institute (VHVI) has consistently ranked among the top centers in the country for the implantation of left atrial appendage closure (LAAC) devices.
Feb. 9, 2017—Vanderbilt University Medical Center (VUMC) is the first in the state to enroll patients in a clinical trial testing the effectiveness of the newest implantable device used to reduce stroke risk in patients with non-valvular atrial fibrillation (AF), the most common form of arrhythmia.
Aug. 25, 2016—Peggy Tubb doesn’t recall her exact reaction when she was told she could stop taking blood thinners to treat atrial fibrillation (AF), but the news changed her life.
Jun. 17, 2015—Vanderbilt Heart and Vascular Institute now offers patients with atrial fibrillation (AF) an alternative treatment to reduce their risk of stroke, potentially avoiding the long-term use of blood thinners such as warfarin.
May. 12, 2014—A particular anti-arrhythmia drug provides a targeted treatment for certain forms of atrial fibrillation.
May. 8, 2014—A technique called whole-exome sequencing (WES) has been used for the first time at Vanderbilt University to identify new genetic variations associated with a common disease — a heart rhythm abnormality called atrial fibrillation (AF).
Dec. 13, 2012—A rare genetic variant that occurs more commonly in families of patients with atrial fibrillation (AF) may be a key to better understanding this common and potentially life threatening condition, Vanderbilt University researchers reported this week.